CD274 and small cell lung carcinoma: In March 2020, another anti-PD-L1 antibody, durvalumab, in combination with platinum–etoposide was approved by the FDA as first-line therapy of ES-SCLC patients based on the findings of the CASPIAN trial (NCT03043872).